MA-HOLOGIC
21.9.2021 13:02:08 CEST | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index , the world’s most comprehensive, globally comparative survey about women’s health.
Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls.
Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scored more than 69. Country and territory rankings can be found here . Notably, 40% of those surveyed – equating to about a billion women and girls – said they had not talked to a healthcare professional in the last year, while approximately 60% – about 1.5 billion – were not tested for four common diseases that affect women’s health.
“Women’s health is the cornerstone of families, communities, societies and economies,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “As a leader in the early detection, diagnosis and treatment of women’s health issues, we know firsthand that measurement is the key to improvement. We saw a clear need for more robust, quality data to track and measure women’s health on a global level — particularly as COVID-19 has worsened longstanding healthcare disparities. The Hologic Global Women’s Health Index is the first global survey that uniquely draws from women’s perspectives to determine priorities.”
The Hologic Global Women’s Health Index provides an actionable, science-backed data roadmap for improving life expectancy and quality of life for women and girls worldwide. To help countries and territories determine a strategy for ensuring a healthy future for women, the Index identifies five dimensions of women’s health that explain more than 80% of women’s average life expectancy at birth: Preventive Care, Opinions of Health and Safety, Emotional Health, Individual Health and Basic Needs. In the Index, countries and territories are ranked across each of these five dimensions, then those scores are combined to create an overall ranking. Positive improvements on any of the five dimensions could potentially help women live healthier, longer lives.
“In line with critical UN Sustainable Development Goals and the UN General Assembly theme of ‘Building Resilience Through Hope,’ we urge global healthcare and government leaders to use this data and the five dimensions to guide the development of actionable and measurable plans and investments that prioritize women’s health,” said MacMillan.
While the Hologic Global Women’s Health Index was initiated before COVID-19 affected the world, the pandemic and its effects on the already precarious state of women’s healthcare — including postponed or canceled preventive care examinations, increased poverty levels, and insufficient access to medical facilities and education — have created a more urgent need for world leaders and policymakers to prioritize women’s health.
“The COVID-19 pandemic has both exacerbated and shed light on longstanding gaps in access and quality of healthcare,” said Vipula Gandhi, Senior Managing Partner at Gallup. “The Index provides a baseline from which we can measure the state of women’s health globally. We hope this study will serve as a call to action for world leaders and policymakers as they navigate the global recovery.”
Hologic is committed to conducting the Global Women’s Health Index on a regular basis so world leaders can take action. This commitment builds on Hologic’s more than 30 years of championing women’s health around the world through its products for breast and cervical cancer screening, infectious disease detection, and gynecologic surgery, and its partnerships with numerous global initiatives promoting better access to healthcare .
Country and Territory Rankings Influenced by Disparities in Income and Health Systems
In this first year of the Hologic Global Women’s Health Index, no single country or territory scored more than 69 out of 100. Generally, most countries and territories that lead the world on the Index also lead the world in how much of their wealth they invest back into their health systems, including Austria, Switzerland and Norway. Overall, while women in high-income countries and territories were only 17% of the women surveyed in the Index, they collectively have at least a seven-point lead on the Index over all other women globally.
Conversely, the countries and territories with the lowest scores on the Hologic Global Women’s Health Index all share high income inequality and weak or destabilized infrastructure for healthcare. The countries and territories with the lowest scores on the Index are a mix of mostly low- and lower-middle income economies. Few countries and territories in this group score well in meeting women’s basic needs and are significantly lagging in the Preventive Care dimension.
Universal Challenges Around Preventive Care
“Preventive measures are a crucial first step to combating diseases and infections affecting life expectancy and fertility in women,” said Susan Harvey, MD, Vice-President of Global Medical Affairs, Hologic. “Failing to ensure women get routine testing for cancers, sexually transmitted diseases and infections, and cardiometabolic diseases can lead to larger complications that would otherwise be preventable if monitored or treated early.”
While international testing standards differ, the Hologic Global Women’s Health Index found that within the past 12 months, more than 1.5 billion women were not tested for any of four critical diseases for women: cancer, diabetes, high blood pressure and sexually transmitted diseases/infections (STDs/STIs).
- Just 12% of women worldwide reported being screened for any type of cancer.
- Globally, only about one in five (19%) women reported being screened for diabetes, the sixth leading cause of death for women around the world. In countries and territories with high obesity rates such as the United States, one in three women (34%) reported being tested.
- On average, only one in three women (33%) worldwide had their blood pressure tested despite heart disease being the leading cause of death globally for women and men.
- Fewer than one in nine women (11%) reported being tested for STDs/STIs, which are risk factors for further health issues like HIV, cancer and infertility.
A Holistic Approach to Women’s Health
Collectively, the world in 2020 felt the worst it has in 15 years. Global experiences of worry, stress, sadness and anger continued to rise and set new records. About four in ten women said they experienced worry (40%) and stress (38%) during a lot of the previous day.
Many women surveyed also expressed concerns about their safety and ability to meet basic needs like food and shelter.
- Two in three women (66%) — which translates into roughly 1.7 billion women — cited domestic violence as a widespread problem in their country.
- Nearly one in three (32%) — more than 800 million women — said they are afraid to walk alone at night.
- More than one in three (34%) — nearly 900 million women — said they struggled to afford food in the past year.
- Nearly three in ten (29%) — or nearly 700 million women — said they struggled to afford adequate housing for themselves and their families.
For more information about the Hologic Global Women’s Health Index and year one findings, please visit hologic.womenshealthindex.com .
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Hologic and the Global Women’s Health Index are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries and territories.
About the Gallup World Poll
The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 90% of the world's adult population through annual, nationally representative surveys with comparable metrics across countries and territories. Gallup, Inc. works with organizations across multilaterals, NGOs, private foundations, philanthropies and corporations to measure more than 100 crucial issues affecting people's lives via the World Poll. As a result, the World Poll has become an indispensable tool for global leaders and decision-makers who need to understand the hopes, dreams and behaviors of the people they serve.
Forward Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. There can be no assurance that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.
SOURCE : Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
